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Background: Aggressive statin therapy to reduce low-density lipoprotein (LDL) cholesterol in patients with normal
LDL-cholesterol levels reduces the incidence of future cardiovascular events and enhances atherosclerotic regression
in the common carotid artery. We tried to quantify changes in flow-mediated dilatation (FMD), inflammatory cytokines,
and the severity of carotid arterial stenosis, after aggressive statin administration to patients with normal LDL-
cholesterol levels, and stroke or transient ischemic attack ipsilateral to carotid arterial stenosis.
Methods: Twenty patients with at least a 50% reduction in the diameter of the carotid artery were studied. Atorvastatin
10 mg daily was prescribed for 4 months. Serial changes in the severity of carotid arterial stenosis, and brachial-
artery FMD were evaluated by high-resolution ultrasound. Tumor necrosis factor-alpha (TNF-_), interleukin-1beta
(IL-1`), interleukin-6 (IL-6), vascular cell adhesion molecule (VCAM), intracellular adhesion molecule (ICAM), soluble
endothelin-1 (ET-1), and high-sensitivity C-reactive protein (hs-CRP), were measured before, and after 2 and 4 months
of, atorvastatin treatment.
Results: Atorvastatin significantly decreased plasma levels of total cholesterol and LDL-cholesterol after 1, 2 and
4 months of treatment (p < 0.01). FMD showed significant improvement after only 4 months (10.0% vs 6.8% at
baseline; p = 0.019). The overall severity of carotid arterial lesions was not significantly reduced by atorvastatin.
Changes in TNF-_, IL-1`, IL-6 and ET-1 showed trends towards a progressive decline after atorvastatin, but none
of the cytokines was reduced significantly. FMD did not correlate with the severity of carotid arterial stenosis, lipid
profile, or cytokine levels.
Conclusion: Atorvastatin effectively reduced plasma concentrations of total cholesterol and LDL-cholesterol, and
had beneficial effects on endothelial function, in Chinese patients with carotid arterial stenosis and normal LDL-
cholesterol levels. [J Chin Med Assoc 2005;68(2):53–58]
Key Words: carotid arterial stenosis, cytokines, duplex Doppler ultrasound, hydroxymethylglutaryl-CoA reductase
inhibitors, vascular endothelium
Introduction
Endothelial dysfunction has been demonstrated in
adults with established atherosclerosis, and is also an
important early event in atherogenesis.1 Dysfunction
of the endothelium is a critical factor in the patho-
genesis of several vascular diseases and thrombus
formation.2,3 Noninvasive evaluation of brachial-artery
reactivity (endothelium-dependent vasodilatation;
flow-mediated dilatation [FMD]) using B-mode
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ultrasound is a useful surrogate for detecting systemic
endothelial dysfunction in several diseases.4–7 Our
previous study found that patients with symptomatic
carotid arterial stenosis had impaired FMD compared
with controls and patients with asymptomatic caro-
tid arterial stenosis.8 Thus, endothelial dysfunction
contributed to cerebral ischemic events and stenotic
lesions of the carotid artery. These findings suggested
that aggressive treatment to improve endothelial
function might prevent future cerebrovascular events.
Preliminary reports in stroke patients demonstrated
that statins might shorten hospital stay and help to
control refractory transient ischemic attacks.9,10
The National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III) recommends
an optimal low-density lipoprotein (LDL) cholesterol
level of less than 100 mg/dL for patients at high
cardiovascular risk. Further LDL-cholesterol reduc-
tions, to levels far below 100 mg/dL, are of unknown
benefit, although some reports have suggested that
treatment to “ultra-low” values may provide superior
outcomes.11–13 However, the mechanisms of statin
benefit in patients with normal LDL-cholesterol levels
are not clear. Besides their lipid-lowering effects,
statins have other therapeutic effects, including endo-
thelial protection, and antioxidant, anti-inflammatory
and antiplatelet effects. Clinically, statin therapy has
shown improvements in FMD, and reduced plasma
concentrations of inflammatory cytokines. A recent,
randomized trial demonstrated superior atherosclerotic
regression in the common carotid artery in patients
treated to lower LDL-cholesterol levels.14
Whether aggressive lipid-lowering therapy might
accelerate regression of atherosclerotic lesions that
cause carotid arterial stenosis is also unclear. We pro-
posed that the beneficial effects of statin therapy in
patients with normal plasma cholesterol levels might
result from improved endothelial function, or from
anti-inflammatory effects. We thus conducted the
present study to evaluate changes in carotid-plaque
severity, FMD, and inflammatory cytokines, after
atorvastatin administration to patients with carotid
arterial stenosis and normal plasma cholesterol levels.
Methods
Patient selection
From February 1 to July 31, 2001, a total of 1,152
consecutive patients who received high-resolution du-
plex ultrasound examination of the carotid arteries
were prospectively evaluated. Ultrasound was carried
out with a computed, high-frequency ultrasound sys-
tem (Hewlett Packard, Sonos 5500, Andover, MA,
USA), with a linear multifrequency 7.5 MHz probe
for B-mode imaging and 3.6 MHz probe for pulsed-
wave Doppler velocity measurement. Pulsed-wave
Doppler velocities were determined at the center of
the narrowest carotid arterial lesion. Sixty-two patients
who satisfied the study criteria for significant carotid
arterial stenosis were screened: (1) more than 50%
focal diameter reduction on B-mode images; and (2)
peak systolic velocity at the stenotic site > 120 cm/sec,
or more than twice the peak systolic velocity at a
nearby non-stenotic segment. Patients were excluded
for the following reasons: plasma LDL-cholesterol
concentration above 130 mg/dL (n = 12); currently
receiving lipid-lowering therapy (n = 16); unstable
vital signs or heart failure (n = 6); severe disabling
stroke (n = 7); or severe peripheral vascular insuffi-
ciency in the upper limbs (n = 1). Thus, 20 patients
(aged 62–80 years; 15 males) with carotid arterial
stenosis and normal LDL-cholesterol concentrations
were recruited. All participants signed informed consent
before entering the study, which was approved by the
local Institutional Review Board.
Study protocol
All recruited patients underwent ultrasound examina-
tions in the morning after an overnight fast. All vaso-
active medication was withheld at least 12 hours be-
fore testing. Fasting blood samples were obtained
from all patients. After centrifugation, all plasma sam-
ples were frozen and stored at –20ºC until assay. A
detailed medical history was taken and a neurologic
examination performed during the first visit. Then,
treatment was started with atorvastatin 10 mg daily for
4 months. Patients were asked to return every month,
and any reported clinical or adverse events were re-
corded. FMD was measured, and blood samples col-
lected, after 1, 2 and 4 months of treatment. All pa-
tients underwent ultrasound examination after 2 and
4 months of treatment.
As described previously,4,5,8 patients were assessed
in a temperature-controlled room (25ºC) with the left
arm in the recumbent position. High-frequency
ultrasound was used to measure changes in brachial-
artery diameter in response to reactive hyperemia
(leading to FMD), and in response to 0.4 mg sublin-
gual nitroglycerin (leading to nitroglycerin-induced,
endothelium-independent dilatation). Using 7.5 MHz
linear-array ultrasound, the brachial artery was longi-
tudinally imaged approximately 2–10 cm proximal
to the antecubital crease, after at least 10 minutes’ rest
in the supine position. Hyperemia was induced by
inflating a pneumatic cuff placed around the arm,
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above the scanned part of the artery, to 200 mmHg for
5 minutes, and then deflating the cuff. The artery was
scanned before cuff inflation and immediately, 1, 3
and 5 minutes after deflation. After another 10 minutes’
rest, a further control scan was recorded. A single dose
of nitroglycerin 0.4 mg was administered sublingually
and brachial-artery diameter was recorded after 3
and 5 minutes. Great care was taken to maintain the
transducer in a fixed position relative to the subject’s
arm. Sonographic images were recorded on super-
VHS videotape for subsequent analysis. All vasodila-
tation measurements were made at end diastole
(concurrent with the onset of the QRS complex on
electrocardiogram). For the calculation of FMD, the
change in vessel diameter 1 minute after cuff defla-
tion was divided by the average control diameter.
Endothelium-independent dilatation was calculated
as the change in vessel diameter, 3 minutes after ni-
troglycerin, divided by the average control diameter.
An ultrasound assessment of the cervical carotid
artery was carried out with each subject lying in the
supine position. Using 7.5 MHz linear-array ultra-
sound, the cervical carotid arteries were first scanned
horizontally and then longitudinally. Great care was
taken to maintain the transducer perpendicular to the
artery during all measurements. The intima-media
layer on the far wall was to be clearly seen to ensure the
imaging artery was in axis during measurement. The
maximal thickness of plaque over the carotid artery
was recorded. Scan images were also recorded on
super-VHS videotapes for later analysis.
Plasma glucose concentrations were determined
using the glucose oxidase method. Plasma cholesterol
and triglyceride concentrations were measured after
precipitation of apolipoprotein B-containing lipo-
proteins by phosphotungstic acid and magnesium
chloride reagent.15 LDL-cholesterol concentration was
calculated by the Friedewald equation. Plasma con-
centrations of tumor necrosis factor-alpha (TNF-_),
interleukin-1beta (IL-1`), interleukin-6 (IL-6), soluble
vascular cell adhesion molecule (VCAM), soluble
intracellular adhesion molecule (ICAM), and soluble
endothelin-1 (ET-1), were measured by a commercial
enzyme-linked high sensitivity immunoassay (R&D
Systems, Minneapolis, MN, USA). The assay for high-
sensitivity plasma C-reactive protein (hs-CRP) was
performed by latex-enhanced immunoturbimetry
(Good Biotech Corp, Taichung, Taiwan); the assay
has inter- and intra-assay coefficients of variation of
1.42% and 1.40%, respectively.
Statistical analysis
All values are expressed as mean ( standard deviation.
Comparisons of serial changes in FMD, inflammato-
ry cytokine concentrations, and maximal diameter
reduction of the carotid artery, were analyzed compared
with baseline by non-parametric Wilcoxon’s signed-
rank test. Correlations between measured parameters
were assessed according to Spearman’s method. All
statistical calculations were performed using a com-
mercially available statistical package (Statistical
Package for the Social Sciences, version 9.0 for Win-
dows, Chicago, IL, USA). A p value of less than 0.05
was considered statistically significant.
Results
Atorvastatin significantly decreased plasma levels of
total cholesterol and LDL-cholesterol after 1, 2 and
4 months of treatment (p < 0.001) (Table 1). The
mean LDL-cholesterol level was lowered to less than
70 mg/dL. No patient developed any adverse event
during atorvastatin therapy.
FMD improved only after 4 months’ atorvastatin
treatment (p = 0.019). The severity of carotid arterial
lesions was not significantly reduced by atorvastatin
(Table 2). Changes in inflammatory cytokine levels
after atorvastatin are also listed in Table 2. hs-CRP
decreased significantly after 2 months (p = 0.04), but
demonstrated no significant change after 4 months
(p = 0.852). Atorvastatin tended to produce a pro-
Table 1. Changes in lipid profile during atorvastatin therapy
Atorvastatin therapy
Baseline
After 1 month After 2 months After 4 months
p p p
Total cholesterol (mg/dL) 163.4 ( 37.0 136.1 ( 31.3 0.002 136.4 ( 32.0 0.004 137.7 ( 28.1 0.005
HDL-cholesterol (mg/dL) 144.6 ( 12.9 148.6 ( 11.3 0.136 148.2 ( 11.8 0.116 147.1 ( 11.5 0.278
LDL-cholesterol (mg/dL) 188.3 ( 21.9 160.7 ( 15.6 0.000 162.6 ( 21.4 0.001 163.0 ( 15.5 0.001
Triglyceride (mg/dL) 121.3 ( 60.0 104.1 ( 46.4 0.240 198.2 ( 30.8 0.235 107.8 ( 46.7 0.955
HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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gressive decline in the levels of TNF-_, IL-1`, IL-6
and ET-1. However, none of these cytokines were
reduced significantly after 4 months. Although the
overall severity of carotid arterial stenosis did not
decrease significantly, atorvastatin caused regression
of plaque thickness to less than 30% diameter reduc-
tion in 2 patients, whose LDL cholesterol levels after
4 months were 34.8 mg/dL and 79.4 mg/dL,
respectively. Atorvastatin did not significantly alter
endothelium-independent dilatation induced by
sublingual nitroglycerin.
FMD did not correlate with LDL-cholesterol,
high-density lipoprotein cholesterol, severity of ste-
nosis, or any of the inflammatory cytokines studied.
Plasma concentrations of TNF-_ significantly corre-
lated with those of hs-CRP (r = 0.282; p = 0.028),
IL-1` (r = 0.425; p = 0.001), IL-6 (r = 0.455; p <
0.001), VCAM (r = 0.414; p = 0.001) and ICAM
(r = 0.304; p = 0.018). IL-6 further correlated with
IL-1` (r = 0.353, p = 0.006) and hs-CRP (r = 0.454;
p < 0.001).
Discussion
In this study, atorvastatin caused about a 30% decrease
in plasma LDL-cholesterol concentration in Chinese
patients with normal pretreatment LDL-cholesterol.
The lipid-lowering effect was comparable to that in the
Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-
Lowering Arm (ASCOT—LLA), which demonstrated
a 35% decrease in LDL-cholesterol with atorvastatin
10 mg daily.16 The recent Heart Protection Study12
demonstrated that simvastatin reduced major vascular
events by 25% in patients with baseline LDL-cholesterol
less than 3 mmol/L (115 mg/dL). Observational
studies indicate a continuous positive relationship
between coronary disease risk and blood LDL-
cholesterol concentration, with no definite threshold
below which a reduced concentration fails to be asso-
ciated with reduced risk.17,18 Our study also showed
that atorvastatin improved endothelial function in
patients without hypercholesterolemia when LDL cho-
lesterol was reduced to less than 70 mg/dL. Sheu et al
showed that FMD improved in diabetic patients only
when LDL-cholesterol was less than 80 mg/dL.19 A
subgroup analysis of the ASCOT study also found
improved FMD in patients with normal LDL-
cholesterol.20 As endothelial dysfunction is a critical
factor in the pathogenesis of several vascular diseases
and thrombus formation,2,3 improved endothelial
function seems to be a reasonable mechanism for
reduced cardiovascular events during statin therapy in
patients with normal LDL-cholesterol levels.
Although atorvastatin did not produce significant,
overall regression of carotid arterial lesions in our
study, it markedly reduced the thickness of carotid
arterial stenotic lesions in 2 patients. More interest-
ingly, the effects on plaque regression became evident
within 4 months. Our results also suggested that
aggressive statin treatment in selected patients with
normal plasma cholesterol levels probably helped to
accelerate regression of carotid arterial plaques. We
could not find a target LDL-cholesterol level, or any
other parameter, that ensured regression of carotid
plaques, because multiple factors, besides reduced
Table 2. Changes in flow-mediated dilatation (FMD), nitroglycerin-induced dilatation (NID), carotid arterial stenosis, and
cytokines, during atorvastatin therapy
Atorvastatin therapy
Baseline
After 2 months After 4 months
p p
FMD (%) 6.8 ( 2.8 7.6 ( 4.5 0.204 10.0 ( 4.61 0.019
NID (%) 8.8 ( 7.3 11.3 ( 5.81 0.247 10.5 ( 6.81 0.313
Carotid arterial stenosis (%)* 62.2 ( 17.8 58.2 ( 17.1 0.332 52.0 ( 18.1 0.063
hs-CRP 0.23 ( 0.14 0.20 ( 0.16 0.040 0.27 ( 0.29 0.852
TNF-_ 7.13 ( 8.11 6.61 ( 6.35 0.287 5.30 ( 3.23 0.985
IL-1` 1.31 ( 2.67 0.84 ( 1.23 0.654 0.54 ( 0.54 0.123
IL-6 3.47 ( 6.41 3.27 ( 5.58 0.778 2.79 ( 4.91 0.406
ICAM 269.4 ( 83.11 260.0 ( 93.11 0.370 270.7 ( 92.71 0.765
VCAM 902.1 ( 439.1 827.8 ( 319.1 0.575 825.7 ( 324.9 0.232
Endothelin-1 1.36 ( 1.37 1.20 ( 0.73 0.964 0.97 ( 0.40 0.432
*Carotid arterial stenosis = maximal percentage diameter reduction in carotid arteries. hs-CRP = high-sensitivity C-reactive protein; TNF = tumor
necrosis factor; IL = interleukin; ICAM = intracellular adhesion molecule; VCAM = vascular cell adhesion molecule.
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cholesterol, are likely to be involved in the regression
of arterial stenotic lesions. Kent and Taylor showed
that patients with higher-than-average, on-therapy
CRP levels are most likely to benefit from LDL-
cholesterol reductions beyond the traditional goal of
less than 100 mg/dL.21 In our study, the cytokines
and vasodilatory responses were not significantly
different between patients with and those without re-
gression of carotid arterial lesions, probably because
the response rate was too low and the follow-up period
too short. Prospective studies recruiting more patients
are mandatory to understand the mechanisms of
atherosclerotic plaque regression. Accumulating data
strongly suggest that inflammation plays an impor-
tant role in the process of atherosclerosis.22,23 Such
accentuated inflammatory responses may contribute
to the high level of mortality from coronary heart
disease in these subjects. Inflammatory cytokines,
particularly TNF-_ and IL-1`, stimulate a complex
cascade of events.24,25 Secondary responses include the
release of chemotactic IL-6 and IL-8, upregulation of
leukocyte adhesion molecule, and decreased fibrinoly-
tic activity. Changes in inflammatory cytokines after
atorvastatin administration have been variable.26,27 In
this study, plasma concentrations of TNF-_, IL-1`,
IL-6 and ET-1 showed a trend towards progressive
reduction after atorvastatin therapy. However, none
of these cytokines were reduced significantly or cor-
related with FMD in our small trial. TNF-_ concen-
trations correlated with hs-CRP, IL-1`, IL-6, VCAM
and ICAM concentrations. Thus, TNF-_, as an initia-
tor of the inflammatory cascade, may be useful as a
marker of various inflammatory cytokines in future
clinical studies. Previous studies showed that statins,
including pravastatin, cerivastatin, lovastatin, simvas-
tatin and atorvastatin, reduced circulating levels of
hs-CRP.9,28–31 However, it is unclear if statin therapy
also reduces the levels of hs-CRP or inflammatory
cytokines in patients with carotid stenosis. Our study
showed that atorvastatin significantly reduced hs-
CRP after only 2 months’ treatment. Conversely, the
mean hs-CRP level after 4 months was higher than the
baseline level (not significant). These inconsistent
changes suggest that elevated hs-CRP is a non-specific
marker of inflammation and may be biased in individual
cases or small-scale trials.
There are some limitations to this study. Firstly,
there may have been confounding effects from medica-
tions on vasoreactivity, as we were unable to withdraw
medication from chronically ill patients. Indeed, in all
patients, atorvastatin was an “add-on” drug, and
previous medication was unaltered. The effects of
atorvastatin could, nonetheless, be assessed by com-
paring serial changes in the same individual. Secondly,
the number of patients was small, and the follow-up
period was relatively short. In addition, there are
certain racial differences to consider regarding carotid
arterial lesions. Further large-scale studies in different
ethnic groups are necessary to provide more robust
evidence for the management of patients with carotid
arterial stenosis and normal LDL-cholesterol levels.
In conclusion, 4 months’ atorvastatin therapy im-
proved flow-mediated FMD in patients with carotid
arterial stenosis and normal LDL-cholesterol levels,
but did not cause significant regression of carotid
arterial lesions. The endothelial protective effect of
atorvastatin contributed to the drug’s therapeutic
benefit in patients with normal LDL-cholesterol levels.
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